Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,232 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,064
- Phase 1822
- Phase 1/Phase 2446
- Phase 3425
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis344
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia98
- Autoimmune Diseases81
- Follicular Lymphoma73
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)75
- Assistance Publique - Hôpitaux de Paris69
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center62
- AstraZeneca57
- Mayo Clinic47
- City of Hope Medical Center46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama180
- Florida142
- Arizona140
- New York122
- Massachusetts120
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,232 total
- NCT07518186RecruitingPhase 3
Comparing Two New Myeloma Treatments: JNJ-79635322 vs Teclistamab
This study compares two new antibody-based drugs (JNJ-79635322 and teclistamab) to see which works better for multiple myeloma that has come back or stopped responding to prior treatment. Both drugs are designed to help your immune system fight myeloma cells.
Birmingham, AlabamaAges 18 years+ - NCT05634369RecruitingTeam says not enrollingPhase 1/Phase 2
NK cell and chemotherapy trial for relapsed soft tissue sarcoma
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
South Birmingham, AlabamaAges 2–40 - NCT05879757RecruitingTeam says not enrolling
Real-world HyQvia use for adults with myeloma and weak immunity
This study looks at how HyQvia (an immune-boosting medicine given under the skin) is used in real life for adults with multiple myeloma and secondary immune problems. It may help doctors understand what works best and how patients do when HyQvia is used routinely.
CórdobaAges 18 years+ - NCT05183152RecruitingTeam says not enrolling
Non-invasive brain signal control for assistive devices
This study tests an assistive device that you control using signals from the brain and muscles without surgery. It may help people with movement problems communicate or operate devices using gentle, non-invasive sensing.
Austin, TexasAges 18–80 - NCT06463587RecruitingTeam says not enrollingPhase 3
Oral cladribine for generalized myasthenia gravis
This study tests a new oral medication (cladribine) to see if it can reduce muscle weakness and daily symptoms in people with generalized myasthenia gravis. It compares the drug to a placebo (a pill with no active medicine) to check safety and effectiveness.
Phoenix, ArizonaAges 18 years+ - NCT06514794RecruitingTeam says not enrollingPhase 2
CAR-T cell therapy for T-cell leukemia and lymphoma
This trial tests a new CAR-T cell therapy (WU-CART-007) made from donor cells that target a protein called CD7 on cancer cells. It is for children and adults with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or is still present after treatment.
Duarte, CaliforniaAges 1 year+ - NCT07323173RecruitingPhase 1
Safety study of LBL-047 in healthy adults and lupus patients
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
Bengbu, AnhuiAges 18–60 - NCT07404111RecruitingPhase 1/Phase 2
Study of VV-14305 for thyroid eye disease
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
Livonia, MichiganAges 18–80 - NCT07788859Recruiting
Testing dual-task walking tests in multiple sclerosis
This study looks at how well three different dual-task tests (doing two things at once while walking) work for people with multiple sclerosis. It aims to find reliable and valid ways to assess walking and thinking in MS.
GaziantepAges 18–65 - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Springdale, ArkansasAges 18 years+ - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Duarte, CaliforniaAges 18 years+ - NCT07404865RecruitingPhase 3
Telitacicept for active primary Sjögren's disease
This study tests an investigational drug called telitacicept for people with active primary Sjögren's disease. The goal is to see if it can reduce symptoms like joint pain, fatigue, and swelling better than a placebo.
Chandler, ArizonaAges 18–75 - NCT07127926RecruitingPhase 1
Belumosudil pill vs crushed pill study for chronic GVHD
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
Houston, TexasAges 18 years+ - NCT07076199RecruitingPhase 3
Weekly vs daily insulin for type 1 diabetes
This study tests a new once-weekly insulin (icodec) against a standard daily insulin (glargine), both taken with mealtime insulin. It aims to see which works better to control blood sugar in adults with type 1 diabetes.
Cullman, AlabamaAges 18 years+ - NCT07705737RecruitingPhase 2
Testing Rademikibart for asthma or COPD flare-ups
This trial tests an investigational drug called Rademikibart for people having a severe asthma or COPD flare-up that needs emergency care and steroids. The study aims to see if the drug can help control the flare-up faster and reduce the need for more treatment.
Miami, FloridaAges 18–85 - NCT06442475RecruitingPhase 2
Low-dose mosunetuzumab for untreated indolent B-cell lymphoma
This trial tests a low dose of the drug mosunetuzumab for people with slow-growing B-cell lymphomas (follicular lymphoma or marginal zone lymphoma) who have not had any previous treatment. It aims to see if this drug can help control the disease with fewer side effects.
Seattle, WashingtonAges 18 years+ - NCT07256392Enrolling by invitationPhase 3
Long-term safety of barzolvolimab for chronic hives
This study is a long-term extension of the barzolvolimab trial for people with chronic spontaneous urticaria (CSU). It tests the continued safety and effectiveness of barzolvolimab over a longer period for those who have already completed the initial phase 3 study.
Birmingham, AlabamaAges 18 years+ - NCT06807190Recruiting
Safety tracking study for Awiqli in diabetes
This study monitors how well Awiqli works and any side effects in people with diabetes. It's designed to gather real-world safety information, so you can take Awiqli as your doctor prescribes while contributing to important research.
Koriyama-shi, Fukushima, Fukushima, JapanAges Any age - NCT05858034Recruiting
Study of aging and frailty in people with HIV over 50
This study looks at what makes some people with HIV become “pre-frail” or frail as they get older. It uses questionnaires and other checks to understand challenges to healthy aging and may help improve future support and care.
Winston-Salem, North CarolinaAges 50 years+ - NCT06782230Recruiting
A biobank for rare disease samples and data
This study creates a collection of biological samples and health information from people with rare diseases and their family members. It aims to build a shared resource that can help future research on rare conditions.
San Donato Milanese, MilanAges Any age - NCT07766811Recruiting
Implementing diabetes coaching toolkits in clinics
This study looks at how to put new tools into place to help support teenagers with type 1 diabetes. It focuses on the clinic staff who provide care and support to these teens.
Wilmington, DelawareAges Any age - NCT06978725RecruitingPhase 2/Phase 3
Brepocitinib for skin sarcoidosis
This study tests an oral drug called brepocitinib to see if it can help people with skin sarcoidosis and reduce skin symptoms. It aims to find a better treatment option for this condition.
San Francisco, CaliforniaAges 18 years+ - NCT07219043RecruitingPhase 2
Felzartamab for kidney transplant patients with inflammation
This trial tests a drug called felzartamab to see if it can help people who have a type of kidney inflammation after a transplant, even without donor-specific antibodies. It might offer a new treatment option for those who are not getting better on their own.
Loma Linda, CaliforniaAges 18–74 - NCT07256158RecruitingPhase 3
Reducing radiation for early unfavorable Hodgkin lymphoma
This trial tests whether a lower dose of radiation, guided by PET scans, is safe and effective for people with early-stage but unfavorable Hodgkin lymphoma. It aims to reduce side effects while keeping the treatment strong.
AlessandriaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,232 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,656 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.